Grace Guzman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Grace Guzman has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Angela L. Tyner
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, USA
4 shared publications - Ansu O. Perekatt
Department of Chemistry and Chemical Biology, Stevens Institute of Technology
4 shared publications - Hui Xie
Arthritis Research Canada, Vancouver, Canada
4 shared publications Jessica J. Gierut
4 shared publications- Michael I. Chastkofsky
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611
4 shared publications - Priya Mathur
Department of Mathematics, Poornima Institute of Engineering & Technology, Jaipur, Rajasthan, 302022, India
4 shared publications
Latest Publications
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (12)
Overexpression of HMGB1 in hepatocytes accelerates PTEN inactivation-induced liver cancer
Background: Liver cancer is increasing due to the rise in metabolic dysfunction-associated steatohepatitis (MASH). High-mobility group box-1 (HMGB1) is involved in the pathogenesis of chronic liver disease, but its role in MASH-associated liver cancer is unknown. We hypothesized that an increase in hepatocyte-derived HMGB1 in a mouse model of inactivation of PTEN that causes MASH could promote MASH-induced tumorigenesis. Methods: We analyzed publicly available transcriptomics datasets, and to explore the effect of overexpressing HMGB1 in cancer progression, we injected 1.5-month-old Pten ∆Hep mice with adeno-associated virus serotype-8 (AAV8) vectors to overexpress HMGB1-EGFP or EGFP, and sacrificed them at 3, 9 and 11 months of age. Results: We found that HMGB1 mRNA increases in human MASH and MASH-induced hepatocellular carcinoma (MASH-HCC) compared to healthy livers. Male and female Pten ∆Hep mice overexpressing HMGB1 showed accelerated liver tumor development at 9 and 11 months, respectively, with increased tumor size and volume, compared to control Pten ∆Hep mice. Moreover, Pten ∆Hep mice overexpressing HMGB1, had increased incidence of mixed HCC-intrahepatic cholangiocarcinoma (iCCA). All iCCAs were positive for nuclear YAP and SOX9. Male Pten ∆Hep mice overexpressing HMGB1 showed increased cell proliferation and F4/80+ cells at 3 and 9 months. Conclusion: Overexpression of HMGB1 in hepatocytes accelerates liver tumorigenesis in Pten ∆Hep mice, enhancing cell proliferation and F4/80+ cells to drive MASH-induced liver cancer.
- 1 December 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (12)
Open AccessOverexpression of HMGB1 in hepatocytes accelerates PTEN inactivation-induced liver cancer
Background: Liver cancer is increasing due to the rise in metabolic dysfunction-associated steatohepatitis (MASH). High-mobility group box-1 (HMGB1) is involved in the pathogenesis of chronic liver disease, but its role in MASH-associated liver cancer is unknown. We hypothesized that an increase in hepatocyte-derived HMGB1 in a mouse model of inactivation of PTEN that causes MASH could promote MASH-induced tumorigenesis. Methods: We analyzed publicly available transcriptomics datasets, and to explore the effect of overexpressing HMGB1 in cancer progression, we injected 1.5-month-old Pten ∆Hep mice with adeno-associated virus serotype-8 (AAV8) vectors to overexpress HMGB1-EGFP or EGFP, and sacrificed them at 3, 9 and 11 months of age. Results: We found that HMGB1 mRNA increases in human MASH and MASH-induced hepatocellular carcinoma (MASH-HCC) compared to healthy livers. Male and female Pten ∆Hep mice overexpressing HMGB1 showed accelerated liver tumor development at 9 and 11 months, respectively, with increased tumor size and volume, compared to control Pten ∆Hep mice. Moreover, Pten ∆Hep mice overexpressing HMGB1, had increased incidence of mixed HCC-intrahepatic cholangiocarcinoma (iCCA). All iCCAs were positive for nuclear YAP and SOX9. Male Pten ∆Hep mice overexpressing HMGB1 showed increased cell proliferation and F4/80+ cells at 3 and 9 months. Conclusion: Overexpression of HMGB1 in hepatocytes accelerates liver tumorigenesis in Pten ∆Hep mice, enhancing cell proliferation and F4/80+ cells to drive MASH-induced liver cancer.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Description of Supplemental Figures from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessDescription of Supplemental Figures from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer
Supplemental Figure; Additional PTK6 localization and expression data
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer
Supplemental Figure; Additional PTK6 localization and expression data
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer
Supplemental Figure: Differential activation of p38 in breast and colon cancer cell lines
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer
Supplemental Figure: Differential activation of p38 in breast and colon cancer cell lines
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer
Supplemental Figure: Decreased PTK6 Expression in Tumors in Oncomine Datasets
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer
Supplemental Figure: Decreased PTK6 Expression in Tumors in Oncomine Datasets
- 7 March 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (8) , 906-910
Single-dose eculizumab as part of a modified desensitization protocol for ABO-incompatible living donor liver transplantation
An abstract is unavailable. This article is available as a PDF only.
- 7 March 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (8) , 906-910
Single-dose eculizumab as part of a modified desensitization protocol for ABO-incompatible living donor liver transplantation
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 9 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-19
Splicing factor SRSF1 deficiency in the liver triggers NASH-like pathology and cell death
Regulation of RNA processing contributes profoundly to tissue development and physiology. Here, we report that serine-arginine-rich splicing factor 1 (SRSF1) is essential for hepatocyte function and survival. Although SRSF1 is mainly known for its many roles in mRNA metabolism, it is also crucial for maintaining genome stability. We show that acute liver damage in the setting of targeted SRSF1 deletion in mice is associated with the excessive formation of deleterious RNA–DNA hybrids (R-loops), which induce DNA damage. Combining hepatocyte-specific transcriptome, proteome, and RNA binding analyses, we demonstrate that widespread genotoxic stress following SRSF1 depletion results in global inhibition of mRNA transcription and protein synthesis, leading to impaired metabolism and trafficking of lipids. Lipid accumulation in SRSF1-deficient hepatocytes is followed by necroptotic cell death, inflammation, and fibrosis, resulting in NASH-like liver pathology. Importantly, SRSF1-depleted human liver cancer cells recapitulate this pathogenesis, illustrating a conserved and fundamental role for SRSF1 in preserving genome integrity and tissue homeostasis. Thus, our study uncovers how the accumulation of detrimental R-loops impedes hepatocellular gene expression, triggering metabolic derangements and liver damage.
- 9 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-19
Open AccessSplicing factor SRSF1 deficiency in the liver triggers NASH-like pathology and cell death
Regulation of RNA processing contributes profoundly to tissue development and physiology. Here, we report that serine-arginine-rich splicing factor 1 (SRSF1) is essential for hepatocyte function and survival. Although SRSF1 is mainly known for its many roles in mRNA metabolism, it is also crucial for maintaining genome stability. We show that acute liver damage in the setting of targeted SRSF1 deletion in mice is associated with the excessive formation of deleterious RNA–DNA hybrids (R-loops), which induce DNA damage. Combining hepatocyte-specific transcriptome, proteome, and RNA binding analyses, we demonstrate that widespread genotoxic stress following SRSF1 depletion results in global inhibition of mRNA transcription and protein synthesis, leading to impaired metabolism and trafficking of lipids. Lipid accumulation in SRSF1-deficient hepatocytes is followed by necroptotic cell death, inflammation, and fibrosis, resulting in NASH-like liver pathology. Importantly, SRSF1-depleted human liver cancer cells recapitulate this pathogenesis, illustrating a conserved and fundamental role for SRSF1 in preserving genome integrity and tissue homeostasis. Thus, our study uncovers how the accumulation of detrimental R-loops impedes hepatocellular gene expression, triggering metabolic derangements and liver damage.
- Open Access
- 10 November 2022
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 8 (12) , e1405
Hilar Biliary Amputation Neuroma Following Liver Transplant: A Case Report and Review of the Literature for this Diagnostic and Therapeutic Challenge
- 10 November 2022
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 8 (12) , e1405
Open AccessHilar Biliary Amputation Neuroma Following Liver Transplant: A Case Report and Review of the Literature for this Diagnostic and Therapeutic Challenge
- Open Access
- 3 November 2021
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 6 (4) , 692-709
Role of Hepatocyte‐Derived Osteopontin in Liver Carcinogenesis
Osteopontin (OPN) expression correlates with tumor progression in many cancers, including hepatocellular carcinoma (HCC); however, its role in the onset of HCC remains unclear. We hypothesized that increased hepatocyte‐derived OPN is a driver of hepatocarcinogenesis. Analysis of a tissue microarray of 366 human samples revealed a continuous increase in OPN expression during hepatocarcinogenesis. In patients with cirrhosis, a transcriptome‐based OPN correlation network was associated with HCC incidence along 10 years of follow‐up, together with messenger RNA (mRNA) signatures of carcinogenesis. After diethylnitrosamine (DEN) injection, mice with conditional overexpression of Opn in hepatocytes (Opn Hep transgenic [Tg]) showed increased tumor burden. Surprisingly, mice with conditional ablation of Opn in hepatocytes (Opn ΔHep) expressed a similar phenotype. The acute response to DEN was reduced in Opn ΔHep, which also showed more cancer stem/progenitor cells (CSCs, CD44+AFP+) at 5 months. CSCs from Opn Hep Tg mice expressed several mRNA signatures known to promote carcinogenesis, and mRNA signatures from Opn Hep Tg mice were associated with poor outcome in human HCC patients. Treatment with rOPN had little effect on CSCs, and their progression to HCC was similar in Opn −/− compared with wild‐type mice. Finally, ablation of Cd44, an OPN receptor, did not reduce tumor burden in Cd44 −/− Opn Hep Tg mice. Conclusions: Hepatocyte‐derived OPN acts as a tumor suppressor at physiological levels by controlling the acute response to DEN and the presence of CSCs, while induction of OPN is pro‐tumorigenic. This is primarily due to intracellular events rather that by the secretion of the protein and receptor activation.
- 3 November 2021
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 6 (4) , 692-709
Open AccessRole of Hepatocyte‐Derived Osteopontin in Liver Carcinogenesis
Osteopontin (OPN) expression correlates with tumor progression in many cancers, including hepatocellular carcinoma (HCC); however, its role in the onset of HCC remains unclear. We hypothesized that increased hepatocyte‐derived OPN is a driver of hepatocarcinogenesis. Analysis of a tissue microarray of 366 human samples revealed a continuous increase in OPN expression during hepatocarcinogenesis. In patients with cirrhosis, a transcriptome‐based OPN correlation network was associated with HCC incidence along 10 years of follow‐up, together with messenger RNA (mRNA) signatures of carcinogenesis. After diethylnitrosamine (DEN) injection, mice with conditional overexpression of Opn in hepatocytes (Opn Hep transgenic [Tg]) showed increased tumor burden. Surprisingly, mice with conditional ablation of Opn in hepatocytes (Opn ΔHep) expressed a similar phenotype. The acute response to DEN was reduced in Opn ΔHep, which also showed more cancer stem/progenitor cells (CSCs, CD44+AFP+) at 5 months. CSCs from Opn Hep Tg mice expressed several mRNA signatures known to promote carcinogenesis, and mRNA signatures from Opn Hep Tg mice were associated with poor outcome in human HCC patients. Treatment with rOPN had little effect on CSCs, and their progression to HCC was similar in Opn −/− compared with wild‐type mice. Finally, ablation of Cd44, an OPN receptor, did not reduce tumor burden in Cd44 −/− Opn Hep Tg mice. Conclusions: Hepatocyte‐derived OPN acts as a tumor suppressor at physiological levels by controlling the acute response to DEN and the presence of CSCs, while induction of OPN is pro‐tumorigenic. This is primarily due to intracellular events rather that by the secretion of the protein and receptor activation.
- Open Access
- 28 June 2020
- Published by Springer Nature in Cureus
- Vol. 12 (6) , e8889
A Case of Classic Hodgkin Lymphoma Involving the Uterine Cervix Presenting As Vaginal Spotting
Classic Hodgkin lymphoma (CHL) is a clonal lymphoid neoplasm derived from B cells. CHL usually involves the lymph nodes. Although cases with extranodal involvement by CHL have been reported, the involvement of the uterine cervix by CHL is an extremely uncommon phenomenon. Herein, we report an unusual case of a 51-year-old female with nodular sclerosis CHL, diagnosed initially via right inguinal lymph node biopsy. After two cycles of chemotherapy, she presented with vaginal spotting and CT scan demonstrated a uterine cervical lesion with hypermetabolic activity. Tissue biopsy sections of the uterine cervix showed cellular infiltrate consisting of large atypical cells including many lacunar cells and occasional Reed-Sternberg cells in the background of mixed reactive cells including small- to medium-sized lymphocytes, histiocytes, plasma cells, eosinophils, and neutrophils. Immunohistochemical stains show that the large atypical cells are positive for CD30, CD15, MUM-1, and weakly positive for PAX-5. In situ hybridization for Epstein-Barr virus-encoded RNA (EBER) is negative. The morphological and immunohistochemical findings were consistent with involvement by nodular sclerosis CHL. This case demonstrates a rare presentation of CHL that may pose a diagnostic problem if its existence is not considered in the differential diagnosis. Furthermore, we reviewed the literature and only found two previous publications described uterine cervix involvement by CHL. Although it is very rare, CHL, involvement should be included in the differential diagnosis and an appropriate work-up should be performed to evaluate CHL involvement of cervix when patients with CHL present with signs or symptoms suggesting a cervical lesion.
- 28 June 2020
- Published by Springer Nature in Cureus
- Vol. 12 (6) , e8889
Open AccessA Case of Classic Hodgkin Lymphoma Involving the Uterine Cervix Presenting As Vaginal Spotting
Classic Hodgkin lymphoma (CHL) is a clonal lymphoid neoplasm derived from B cells. CHL usually involves the lymph nodes. Although cases with extranodal involvement by CHL have been reported, the involvement of the uterine cervix by CHL is an extremely uncommon phenomenon. Herein, we report an unusual case of a 51-year-old female with nodular sclerosis CHL, diagnosed initially via right inguinal lymph node biopsy. After two cycles of chemotherapy, she presented with vaginal spotting and CT scan demonstrated a uterine cervical lesion with hypermetabolic activity. Tissue biopsy sections of the uterine cervix showed cellular infiltrate consisting of large atypical cells including many lacunar cells and occasional Reed-Sternberg cells in the background of mixed reactive cells including small- to medium-sized lymphocytes, histiocytes, plasma cells, eosinophils, and neutrophils. Immunohistochemical stains show that the large atypical cells are positive for CD30, CD15, MUM-1, and weakly positive for PAX-5. In situ hybridization for Epstein-Barr virus-encoded RNA (EBER) is negative. The morphological and immunohistochemical findings were consistent with involvement by nodular sclerosis CHL. This case demonstrates a rare presentation of CHL that may pose a diagnostic problem if its existence is not considered in the differential diagnosis. Furthermore, we reviewed the literature and only found two previous publications described uterine cervix involvement by CHL. Although it is very rare, CHL, involvement should be included in the differential diagnosis and an appropriate work-up should be performed to evaluate CHL involvement of cervix when patients with CHL present with signs or symptoms suggesting a cervical lesion.